Henry Schein (HSIC) FY2024 10-K Annual Report
Filed: Feb 25, 2025
Consumer Discretionary
Wholesale-Medical, Dental & Hospital Equipment & SuppliesSEC EDGAR Henry Schein (HSIC) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 25, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Henry Schein FY2024 10-K Analysis
Business Overview
- • Core business model: Global distributor and manufacturer of dental, medical, specialty healthcare products, and practice management technologies
- • New segment reporting structure in 2024: three segments — Global Distribution and Value-Added Services, Global Specialty Products, Global Technology
- • Strategic shift: 2024 restructuring plan initiated for integration and efficiency following recent acquisitions and prior restructuring completion
- • Quantitative highlight: Net sales increased 2.7% to $12.67B; Global Specialty Products sales up 8.7%, driven by acquisitions of TriMed, Biotech Dental, S.I.N.
- • Noteworthy fact: Restructuring charges of $73M in 2024 including $13M goodwill impairment related to Global Specialty Products segment disposal
Management Discussion & Analysis
- • Revenue $12.339B, down 2.4% YoY; Global Dental flat at $6.65B (+0.3%), Global Medical down 10% to $3.91B
- • Gross margin 31.7% vs 31.3%; Global Specialty Products margin 54.1% vs 53.3%, Global Technology margin 67.4% vs 69.2%, Global Distribution margin 25.6% vs 25.2%
- • Best segment: Global Technology sales up 9.6% to $602M with 67.4% gross margin; worst: Global Medical sales down 10% to $3.91B
- • Operating expenses $3.245B (26.3% of sales) vs $3.084B (24.4%); net cash from operations $848M vs $500M; capex and acquisitions $430M outflow vs $1.135B prior year; repurchases ongoing with $380M remaining authorization
- • Management impacted by 2023 cyber incident affecting sales and working capital; expects continued share repurchases and monitors emerging global tax rules (OECD Pillar Two) and market conditions
Risk Factors
- • Regulatory risk: non-compliance with EU Medical Device Regulation impacting global specialty products manufacturing
- • Geopolitical risk: disruptions from ongoing wars including Ukraine and Israel-Gaza conflicts affecting international trade and operations
- • Operational risk: October 2023 cyberattack caused $9M expenses and decreased sales in North American and European distribution segments
- • Competitive risk: pressure from third-party online commerce sites challenging traditional distribution channels
- • Financial risk: reliance on $60M cyber insurance claim with $20M still under review potentially affecting coverage realization
Henry Schein FY2024 Key Financial MetricsXBRL
Revenue
$12.7B
▲ +2.7% YoY
Net Income
$390M
▼ -6.3% YoY
Gross Margin
31.7%
▲ +40bp YoY
Operating Margin
4.9%
▼ -8bp YoY
Net Margin
3.1%
▼ -29bp YoY
ROE
11.5%
▲ +11bp YoY
Total Assets
$10.2B
▼ -3.4% YoY
EPS (Diluted)
$3.05
▼ -3.5% YoY
Operating Cash Flow
$848M
▲ +69.6% YoY
Source: XBRL data from Henry Schein FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Henry Schein Annual Reports
Get deeper insights on Henry Schein
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.